Molecular aspects of dopaminergic neurodegeneration: Gene-environment interaction in parkin dysfunction

International Journal of Environmental Research and Public Health

Volumn 8, Issue 12, 2011, Pages 4702-4713

  Ali, Syed F ^a   Binienda, Zbigniew K ^a   Imam, Syed Z ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Dopaminergic; Environment; Gene; Parkin; Parkinson's disease

Indexed keywords

ABELSON KINASE; ALPHA SYNUCLEIN; IMATINIB; LEVODOPA; MANEB; PARAQUAT; PARKIN; ROTENONE;

ALPHA SYNUCLEIN GENE; DJ 1 GENE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LRRK2 GENE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKIN GENE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PINK1 GENE; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UCHL 1 GENE;

EID: 84055193728     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph8124702     Document Type: Review

References (51)

1. Siderowf, A.; Stern, M. Update on Parkinson disease. Ann. Intern. Med. 2003, 138, 651-658.
2. Goedert, M. Parkinson's disease and other alpha-synucleinopathies. Clin. Chem. Lab Med. 2001, 39, 308-312.
3. Schlossmacher, M.G.; Frosch, M.P.; Gai, W.P.; Medina, M.; Sharma, N.; Forno, L.; Ochiishi, T.; Shimura, H.; Sharon, R.; Hattori, N., et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 2002, 160, 1655-1667.
4. Petrucelli, L.; Dawson, T.M. Mechanism of neurodegenerative disease: Role of the ubiquitin proteasome system. Ann. Med. 2004, 36, 315-320.
5. Moore, D.J.; Dawson, V.L.; Dawson, T.M. Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. Neuromolecular Med. 2003, 4, 95-108.
6. Gu, Z.; Nakamura, T.; Yao, D.; Shi, Z.Q.; Lipton, S.A. Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson's disease. Cell Death Differ. 2005, 12, 1202-1204.
7. Vance, J.M.; Ali, S.F.; Bradley, W.G.; Singer, C.; Di Monte, D.A. Gene-environment interaction in Parkinson's disease and other forms of parkinsonism. Neurotoxicology 2010, 31, 598-602.
8. Dawson, T.M.; Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302, 819-822.
9. Gao, H.M.; Hong, J.S. Gene-environment interactions: Key to unraveling the mystery of Parkinson's disease. Prog. Neurobiol. 2011, 94, 1-19.
10. Kahle, P.J.; Haass, C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep. 2004, 5, 681-685.
11. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K.; Suzuki, T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25, 302-305.
12. Moore, D.J.; West, A.B.; Dawson, V.L.; Dawson, T.M. Molecular pathophysiology of Parkinson's disease. Ann. Rev. Neurosci. 2005, 28, 57-87.
13. Ko, H.S.; von Coelln, R.; Sriram, S.R.; Kim, S.W.; Chung, K.K.; Pletnikova, O.; Troncoso, J.; Johnson, B.; Saffary, R.; Goh, E.L., et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 2005, 25, 7968-7978.
14. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392, 605-608.
15. Lucking, C.B.; Durr, A.; Bonifati, V.; Vaughan, J.; De, M.G.; Gasser, T.; Harhangi, B.S.; Meco, G.; Denefle, P.; Wood, N.W., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 2000, 342, 1560-1567.
16. Mata, I.F.; Lockhart, P.J.; Farrer, M.J. Parkin genetics: One model for Parkinson's disease. Hum. Mol. Genet. 2004, 1, R127-R133.
17. McNaught, K.S.; Mytilineou, C.; Jnobaptiste, R.; Yabut, J.; Shashidharan P.; Jennert, P., Olanow, C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures, J. Neurochem. 2002, 81, 301-306.
18. Foroud, T.; Uniacke, S.K.; Liu, L.; Pankratz, N.; Rudolph, A.; Halter, C.; Shults, C.; Marder, K.; Conneally, P.M.; Nichols, W.C. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003, 60, 796-801.
19. West, A.B.; Maraganore, D.; Crook, J.; Lesnick, T.; Lockhart, P.J.; Wilkes, K.M.; Kapatos, G.; Hardy, J.A.; Farrer, M.J. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum. Mol. Genet. 2002, 11, 2787-2792.
20. Feany, M.B.; Pallanck, L.J. Parkin: A multipurpose neuroprotective agent? Neuron 2003, 38, 13-16.
21. Higashi, Y.; Asanuma, M.; Miyazaki, I.; Hattori, N.; Mizuno, Y.; Ogawa, N. Parkin attenuates manganese-induced dopaminergic cell death. J. Neurochem. 2004, 89, 1490-1497.
22. Petrucelli, L.; O'Farrell, C.; Lockhart, P.J.; Baptista, M.; Kehoe, K.; Vink, L.; Choi, P.; Wolozin, B.; Farrer, M.; Hardy, J.; Cookson, M.R. Parkin protects against the toxicity associated with mutant alpha-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36, 1007-1019.
23. Tsai, Y.C.; Fishman, P.S.; Thakor, N.V.; Oyler, G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 2003, 278, 22044-22055.
24. Takahashi, R.; Imai, Y.; Hattori, N.; Mizuno, Y. Parkin and endoplasmic reticulum stress. Ann. NY Acad. Sci. 2003, 991, 101-106.
25. Yang, Y.; Nishimura, I.; Imai, Y.; Takahashi, R.; Lu, B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003, 37, 911-924.
26. Staropoli, J.F.; McDermott, C.; Martinat, C.; Schulman, B.; Demireva, E.; Abeliovich, A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003, 37, 735-749.
27. Darios, F.; Corti, O.; Lucking, C.B.; Hampe, C.; Muriel, M.P.; Abbas, N.; Gu, W.J.; Hirsch, E.C.; Rooney, T.; Ruberg, M.; Brice, A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 2003, 12, 517-526.
28. Jiang, H.; Ren, Y.; Zhao, J.; Feng, J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 2004, 13, 1745-1754.
29. Zhang, Y.; Gao, J.; Chung, K.K.; Huang, H.; Dawson, V.L.; Dawson, T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicleassociated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 2000, 97, 13354-13359.
30. Lim, K.L.; Chew, K.C.; Tan, J.M.; Wang, C.; Chung, K.K.; Zhang, Y.; Tanaka, Y.; Smith, W.; Engelender, S.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: Implications for Lewy body formation. J. Neurosci. 2005, 25, 2002-2009.
31. Kalia, S.K.; Lee, S.; Smith, P.D.; Liu, L.; Crocker, S.J.; Thorarinsdottir, T.E.; Glover, J.R.; Fon, E.A.; Park, D.S.; Lozano, A.M. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 2004, 44, 931-945.
32. Yamada, M.; Mizuno, Y.; Mochizuki, H. Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease. Hum. Gene Ther. 2005, 16, 262-270.
33. Lo, B.C.; Schneider, B.L.; Bauer, M.; Sajadi, A.; Brice, A.; Iwatsubo, T.; Aebischer, P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2004, 101, 17510-17515.
34. Rosen, K.M.; Veereshwarayya, V.; Moussa, C.E.; Fu, Q.; Goldberg, M.S.; Schlossmacher, M.G.; Shen, J.; Querfurth, H.W. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J. Biol. Chem. 2006, 281, 12809-12816.
35. Chung, K.K.; Thomas, B.; Li, X.; Pletnikova, O.; Troncoso, J.C.; Marsh, L.; Dawson, V.L.; Dawson, T.M. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004, 304, 1328-1331.
36. Yamamoto, A.; Friedlein, A.; Imai, Y.; Takahashi, R.; Kahle, P.J.; Haass, C. Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J. Biol. Chem. 2005, 280, 3390-3399.
37. Lavoie, M.J.; Ostaszewski, B.L.; Weihofen, A.; Schlossmacher, M.G.; Selkoe, D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 2005, 11, 1214-1221.
38. Tieu, K.; Ischiropoulos, H.; Przedborski, S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 2003, 55, 329-335.
39. Ischiropoulos, H.; Beckman, J.S. Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? J. Clin. Invest. 2003, 111, 163-169.
40. Chung, K.K.; Thomas, B.; Li, X.; Pletnikova, O.; Troncoso, J.C.; Marsh, L.; Dawson, V.L.; Dawson, T.M. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004, 304, 1328-1331.
41. Yao, D.; Gu, Z.; Nakamura, T.; Shi, Z.Q.; Ma, Y.; Gaston, B.; Palmer, L.A.; Rockenstein, E.M.; Zhang, Z.; Masliah, E., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. USA 2004, 101, 10810-10814.
42. Brooks, A.I.; Chadwick, C.A.; Gelbard, H.A.; Cory-Slechta, D.A.; Federoff, H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 1999, 823, 1-10.
43. McCormack, A.L.; Thiruchelvam, M.; Manning-Bog, A.B.; Thiffault, C.; Langston, J.W.; Cory-Slechta, D.A.; Di Monte, D.A. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 2002, 10, 119-127.
44. Liou, H.H.; Tsai, M.C.; Chen, C.J.; Jeng, J.S.; Chang, Y.C.; Chen, S.Y.; Chen, R.C. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. Neurology 1997, 48, 1583-1588.
45. Liu, B.; Gao, H.M.; Hong, J.S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: Role of neuroinflammation. Environ. Health Perspect. 2003, 111, 1065-1073.
46. Sherer, T.B.; Kim, J.H.; Betarbet, R.; Greenamyre, J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 2003, 179, 9-16.
47. Gao, H.M.; Hong, J.S.; Zhang, W.; Liu, B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson's disease. J. Neurosci. 2003, 23, 1228-1236.
48. Horowitz, M.P.; Greenamyre, J.T. Gene-environment interactions in Parkinson's disease: The importance of animal modeling. Clin. Pharmacol. Ther. 2010, 88, 467-474.
49. Imam, S.Z.; Zhou, Q.; Yamamoto, A.; Valente, A.J.; Ali, S.F.; Bains, M.; Roberts, J.L.; Kahle, P.J.; Clark, R.A.; Li, S. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: Implications for Parkinson's disease. J. Neurosci. 2011, 31, 157-163.
50. He, Y.; Imam, S.Z.; Dong, Z.; Jankovic, J.; Ali, S.F.; Appel, S.H.; Le, W. Role of nitric oxide in rotenone-induced nigro-striatal injury. J. Neurochem. 2003, 86, 1338-1345.
51. Meng, F.; Yao, D.; Shi, Y.; Kabakoff, J.; Wu, W.; Reicher, J.; Ma, Y.; Moosmann, B.; Masliah, E.; Lipton, S.A.; Gu, Z. Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Mol. Neurodegener. 2011, 6, doi: 10.1186/1750-1326-6-34.